ASX:MXC Argent BioPharma (MXC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argent BioPharma Stock (ASX:MXC) 30 days 90 days 365 days Advanced Chart Get Argent BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.16 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.70%Price TargetN/AConsensus RatingN/A Company Overview MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia. Read More Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MXC Stock News HeadlinesArgent secures deal for Malta manufacturing facility, unlocking US$1m in cost savingsApril 9, 2025 | msn.comArgent soars as cannabinoid-based epilepsy drug gains approval in GermanyApril 2, 2025 | msn.com[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.July 16 at 2:00 AM | Crypto Swap Profits (Ad)Argent BioPharma’s Strategic Moves and CollaborationOctober 31, 2024 | markets.businessinsider.comArgent Biopharma Lists New Shares on ASXOctober 28, 2024 | markets.businessinsider.comArgent BioPharma Issues New Shares Amidst Strategic GrowthOctober 28, 2024 | markets.businessinsider.comArgent BioPharma Secures Funding for Drug DevelopmentOctober 24, 2024 | markets.businessinsider.comCo-Founder of Argent BioPharma Picks Up 3,721% More StockSeptember 15, 2024 | finance.yahoo.comSee More Headlines MXC Stock Analysis - Frequently Asked Questions How were Argent BioPharma's earnings last quarter? Argent BioPharma Limited (ASX:MXC) issued its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include NVIDIA (NVDA), Walt Disney (DIS), Grayscale Bitcoin Trust ETF (GBTC), Tesla (TSLA), AbbVie (ABBV), Advanced Micro Devices (AMD) and AstraZeneca (AZN). Company Calendar Last Earnings2/28/2019Today7/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:MXC CIKN/A Webwww.mgcpharma.com.au Phone61 8 6382 3390FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$17.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-307.40% Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick Ratio0.50 Sales & Book Value Annual SalesA$1.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow25.00 Book ValueA$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares43,850,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.03 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (ASX:MXC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.